Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - a study of the OVCAD consortium

Standard

Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - a study of the OVCAD consortium. / Pils, Dietmar; Bachmayr-Heyda, Anna; Auer, Katharina; Svoboda, Martin; Auner, Veronika; Hager, Gudrun; Obermayr, Eva; Reiner, Angelika; Reinthaller, Alexander; Speiser, Paul; Braicu, Ioana; Sehouli, Jalid; Lambrechts, Sandrina; Vergote, Ignace; Mahner, Sven; Berger, Astrid; Cacsire Castillo-Tong, Dan; Zeillinger, Robert.

in: EUR J CANCER, Jahrgang 50, Nr. 1, 01.01.2014, S. 99-110.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsatzForschungBegutachtung

Harvard

Pils, D, Bachmayr-Heyda, A, Auer, K, Svoboda, M, Auner, V, Hager, G, Obermayr, E, Reiner, A, Reinthaller, A, Speiser, P, Braicu, I, Sehouli, J, Lambrechts, S, Vergote, I, Mahner, S, Berger, A, Cacsire Castillo-Tong, D & Zeillinger, R 2014, 'Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - a study of the OVCAD consortium', EUR J CANCER, Jg. 50, Nr. 1, S. 99-110. https://doi.org/10.1016/j.ejca.2013.09.011

APA

Pils, D., Bachmayr-Heyda, A., Auer, K., Svoboda, M., Auner, V., Hager, G., Obermayr, E., Reiner, A., Reinthaller, A., Speiser, P., Braicu, I., Sehouli, J., Lambrechts, S., Vergote, I., Mahner, S., Berger, A., Cacsire Castillo-Tong, D., & Zeillinger, R. (2014). Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - a study of the OVCAD consortium. EUR J CANCER, 50(1), 99-110. https://doi.org/10.1016/j.ejca.2013.09.011

Vancouver

Bibtex

@article{3fe96350d6c7423bb8ef2a26ae240c0d,
title = "Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - a study of the OVCAD consortium",
abstract = "Cyclin E, coded by the genes CCNE1 and CCNE2, is the main regulator for transition from G1 to S phase determining cell division. CCNE1 and CCNE2 are known oncogenes in many cancer entities. Especially CCNE1 has frequently been associated with gene amplifications in various malignancies, emphasising its role as a putative oncogene. We determined gene expression and copy number of CCNE1 and CCNE2 by quantitative polymerase chain reaction (PCR) from 172 International Federation of Obstetrics and Gynecology (FIGO) II/III/IV stage serous epithelial ovarian cancer (EOC) tissues and analysed its impact on outcome. Furthermore, whole transcriptome gene expression changes correlating with CCNE1 expression were determined by microarray technology, interpreted by Signalling Pathway Impact Analysis (SPIA), Tool for Inferring Network of Genes (TINGe), and illustrated by hive plots. Protein-protein interaction (PPI) networks were also used for the interpretation. Interestingly, and contradictory to most reports and intuitive expectations, high CCNE1 expression correlated with better overall survival (p=0.005) if corrected for usual clinicopathologic parameters and a molecular subclassification. Using different grading systems or only high graded tumours had no impact on this correlation. Copy number of CCNE1 was increased in 25% of cases which correlated highly significantly with expression but showed no impact on outcome. CCNE2 had no impact on outcomes at all. Whole genome transcriptome analysis revealed 1872 differentially expressed genes correlated to CCNE1 expression, which were significantly enriched with genes from five pathways (e.g. cell cycle and viral carcinogenesis pathway were up-regulated and the Fanconi anaemia pathway was down-regulated). High CCNE1 gene expression is a significant and independent predictor for prolonged overall survival in FIGO III/IV EOC patients. This upside down impact of CCNE1 on survival probably reflects the special characteristic of EOC with tumour dissemination in the near anaerobic peritoneal cavity as the predominant cause of death, compared to other cancer entities where distant metastasis are predominantly lethal.",
keywords = "Cell Proliferation, Cyclin E, Cyclins, Female, Gene Amplification, Gene Dosage, Gene Expression, Humans, Middle Aged, Neoplasms, Glandular and Epithelial, Oncogene Proteins, Ovarian Neoplasms, Prognosis, Signal Transduction, Tumor Markers, Biological",
author = "Dietmar Pils and Anna Bachmayr-Heyda and Katharina Auer and Martin Svoboda and Veronika Auner and Gudrun Hager and Eva Obermayr and Angelika Reiner and Alexander Reinthaller and Paul Speiser and Ioana Braicu and Jalid Sehouli and Sandrina Lambrechts and Ignace Vergote and Sven Mahner and Astrid Berger and {Cacsire Castillo-Tong}, Dan and Robert Zeillinger",
note = "Copyright {\textcopyright} 2013 Elsevier Ltd. All rights reserved.",
year = "2014",
month = jan,
day = "1",
doi = "10.1016/j.ejca.2013.09.011",
language = "English",
volume = "50",
pages = "99--110",
journal = "EUR J CANCER",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "1",

}

RIS

TY - JOUR

T1 - Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - a study of the OVCAD consortium

AU - Pils, Dietmar

AU - Bachmayr-Heyda, Anna

AU - Auer, Katharina

AU - Svoboda, Martin

AU - Auner, Veronika

AU - Hager, Gudrun

AU - Obermayr, Eva

AU - Reiner, Angelika

AU - Reinthaller, Alexander

AU - Speiser, Paul

AU - Braicu, Ioana

AU - Sehouli, Jalid

AU - Lambrechts, Sandrina

AU - Vergote, Ignace

AU - Mahner, Sven

AU - Berger, Astrid

AU - Cacsire Castillo-Tong, Dan

AU - Zeillinger, Robert

N1 - Copyright © 2013 Elsevier Ltd. All rights reserved.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Cyclin E, coded by the genes CCNE1 and CCNE2, is the main regulator for transition from G1 to S phase determining cell division. CCNE1 and CCNE2 are known oncogenes in many cancer entities. Especially CCNE1 has frequently been associated with gene amplifications in various malignancies, emphasising its role as a putative oncogene. We determined gene expression and copy number of CCNE1 and CCNE2 by quantitative polymerase chain reaction (PCR) from 172 International Federation of Obstetrics and Gynecology (FIGO) II/III/IV stage serous epithelial ovarian cancer (EOC) tissues and analysed its impact on outcome. Furthermore, whole transcriptome gene expression changes correlating with CCNE1 expression were determined by microarray technology, interpreted by Signalling Pathway Impact Analysis (SPIA), Tool for Inferring Network of Genes (TINGe), and illustrated by hive plots. Protein-protein interaction (PPI) networks were also used for the interpretation. Interestingly, and contradictory to most reports and intuitive expectations, high CCNE1 expression correlated with better overall survival (p=0.005) if corrected for usual clinicopathologic parameters and a molecular subclassification. Using different grading systems or only high graded tumours had no impact on this correlation. Copy number of CCNE1 was increased in 25% of cases which correlated highly significantly with expression but showed no impact on outcome. CCNE2 had no impact on outcomes at all. Whole genome transcriptome analysis revealed 1872 differentially expressed genes correlated to CCNE1 expression, which were significantly enriched with genes from five pathways (e.g. cell cycle and viral carcinogenesis pathway were up-regulated and the Fanconi anaemia pathway was down-regulated). High CCNE1 gene expression is a significant and independent predictor for prolonged overall survival in FIGO III/IV EOC patients. This upside down impact of CCNE1 on survival probably reflects the special characteristic of EOC with tumour dissemination in the near anaerobic peritoneal cavity as the predominant cause of death, compared to other cancer entities where distant metastasis are predominantly lethal.

AB - Cyclin E, coded by the genes CCNE1 and CCNE2, is the main regulator for transition from G1 to S phase determining cell division. CCNE1 and CCNE2 are known oncogenes in many cancer entities. Especially CCNE1 has frequently been associated with gene amplifications in various malignancies, emphasising its role as a putative oncogene. We determined gene expression and copy number of CCNE1 and CCNE2 by quantitative polymerase chain reaction (PCR) from 172 International Federation of Obstetrics and Gynecology (FIGO) II/III/IV stage serous epithelial ovarian cancer (EOC) tissues and analysed its impact on outcome. Furthermore, whole transcriptome gene expression changes correlating with CCNE1 expression were determined by microarray technology, interpreted by Signalling Pathway Impact Analysis (SPIA), Tool for Inferring Network of Genes (TINGe), and illustrated by hive plots. Protein-protein interaction (PPI) networks were also used for the interpretation. Interestingly, and contradictory to most reports and intuitive expectations, high CCNE1 expression correlated with better overall survival (p=0.005) if corrected for usual clinicopathologic parameters and a molecular subclassification. Using different grading systems or only high graded tumours had no impact on this correlation. Copy number of CCNE1 was increased in 25% of cases which correlated highly significantly with expression but showed no impact on outcome. CCNE2 had no impact on outcomes at all. Whole genome transcriptome analysis revealed 1872 differentially expressed genes correlated to CCNE1 expression, which were significantly enriched with genes from five pathways (e.g. cell cycle and viral carcinogenesis pathway were up-regulated and the Fanconi anaemia pathway was down-regulated). High CCNE1 gene expression is a significant and independent predictor for prolonged overall survival in FIGO III/IV EOC patients. This upside down impact of CCNE1 on survival probably reflects the special characteristic of EOC with tumour dissemination in the near anaerobic peritoneal cavity as the predominant cause of death, compared to other cancer entities where distant metastasis are predominantly lethal.

KW - Cell Proliferation

KW - Cyclin E

KW - Cyclins

KW - Female

KW - Gene Amplification

KW - Gene Dosage

KW - Gene Expression

KW - Humans

KW - Middle Aged

KW - Neoplasms, Glandular and Epithelial

KW - Oncogene Proteins

KW - Ovarian Neoplasms

KW - Prognosis

KW - Signal Transduction

KW - Tumor Markers, Biological

U2 - 10.1016/j.ejca.2013.09.011

DO - 10.1016/j.ejca.2013.09.011

M3 - SCORING: Journal article

C2 - 24176298

VL - 50

SP - 99

EP - 110

JO - EUR J CANCER

JF - EUR J CANCER

SN - 0959-8049

IS - 1

ER -